Researchers from the UK have developed a straightforward strategy for making compounds that have the potential to become clinical drugs. By cleverly combining robust chemistry and simple starting materials, the team accessed numerous small, diverse molecules with properties suitable for drug screening.
Even the most successful drug starts small. Pharmaceutical companies screen vast libraries of small compounds for the next lead – a molecule that interacts with a given target such as a protein or receptor. Through structural optimisation, tweaking and testing, the lead then grows into a full-fledged drug, ready for biological trials.
A minimal toolkit of reactions turns small polyfunctional molecules into diverse scaffolds
Read the full article in Chemistry World»
Read the original journal article in ChemComm – it’s free to access until 1st July:
Synthesis of amphiphilic polysuccinimide star copolymers for responsive delivery in plants
Mingsheng Chen, Shaun P. Jensen, Megan R. Hill, Gloria Moore, Zhenli He and Brent S. Sumerlin
Chem. Commun., 2015, Advance Article
DOI: 10.1039/C5CC02726H, Communication
